Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.

Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD.

J Am Coll Cardiol. 2005 Jul 5;46(1):166-72. Erratum in: J Am Coll Cardiol. 2011 Oct 18;58(17):1832.

2.

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD.

Am J Gastroenterol. 2011 Jan;106(1):71-7. doi: 10.1038/ajg.2010.299. Epub 2010 Sep 14.

PMID:
20842109
4.

Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.

Mulders TA, Sivapalaratnam S, Stroes ES, Kastelein JJ, Guerci AD, Pinto-Sietsma SJ.

JACC Cardiovasc Imaging. 2012 Mar;5(3):252-60. doi: 10.1016/j.jcmg.2011.11.014.

5.

Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.

Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P, Musial J.

Arthritis Res Ther. 2011 Jul 20;13(4):R117. doi: 10.1186/ar3402.

6.

Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.

Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators.

Heart. 2006 Sep;92(9):1207-12. Epub 2006 Jan 31.

7.

Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.

Stone PH, Lloyd-Jones DM, Kinlay S, Frei B, Carlson W, Rubenstein J, Andrews TC, Johnstone M, Sopko G, Cole H, Orav J, Selwyn AP, Creager MA; Vascular Basis Study Group.

Circulation. 2005 Apr 12;111(14):1747-55. Epub 2005 Apr 4.

8.

A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.

Sdringola S, Gould KL, Zamarka LG, McLain R, Garner J.

Am Heart J. 2008 Feb;155(2):245-53. doi: 10.1016/j.ahj.2007.10.025. Epub 2007 Dec 19.

PMID:
18215593
9.

Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.

Voros S, Joshi PH, Vazquez G, Roth G, Murrieta L, Rinehart S, Qian Z, Miller J.

J Cardiovasc Comput Tomogr. 2010 May-Jun;4(3):164-72. doi: 10.1016/j.jcct.2010.03.005. Epub 2010 Mar 17.

PMID:
20413364
10.

Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.

Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R.

Circulation. 2006 Jan 24;113(3):427-37. Epub 2006 Jan 16.

11.

Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.

Waheed S, Pollack S, Roth M, Reichek N, Guerci A, Cao JJ.

Atherosclerosis. 2016 Dec;255:193-199. doi: 10.1016/j.atherosclerosis.2016.09.060. Epub 2016 Sep 17.

PMID:
27693004
12.

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D.

J Am Coll Cardiol. 2010 Sep 28;56(14):1079-88. doi: 10.1016/j.jacc.2010.06.015. Erratum in: J Am Coll Cardiol. 2011 Mar 29;57(13):1501.

13.

Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?

Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U.

J Am Coll Cardiol. 2007 Mar 13;49(10):1035-42. Epub 2007 Feb 23.

14.

The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.

Budoff MJ, Kessler P, Gao YL, Qunibi W, Moustafa M, Mao SS.

Acad Radiol. 2008 Jan;15(1):58-61.

PMID:
18078907
15.

A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators.

N Engl J Med. 2005 Jun 9;352(23):2389-97.

17.

Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin.

Manuel-Y-Keenoy B, Vinckx M, Vertommen J, Van Gaal L, De Leeuw I.

Atherosclerosis. 2004 Aug;175(2):369-76.

PMID:
15262194
18.
19.

Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?

Arendt BM, Allard JP.

Am J Gastroenterol. 2011 Jan;106(1):78-80. doi: 10.1038/ajg.2010.310.

PMID:
21212755
20.

Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.

Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF.

J Intern Med. 2005 May;257(5):438-45.

Supplemental Content

Support Center